What is the treatment for myasthenia gravis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The treatment for myasthenia gravis involves several approaches tailored to the patient's symptoms and disease severity, with pyridostigmine bromide administered orally two to four times a day as the first-line treatment, and corticosteroids, immunosuppressive therapy, and thymectomy considered for patients with moderate to severe symptoms or thymoma. The management of myasthenia gravis requires a multidisciplinary approach, involving neurologists, ophthalmologists, and other healthcare professionals.

  • Acetylcholinesterase inhibitors like pyridostigmine (Mestinon) are typically first-line treatments, usually starting at 30-60mg three to four times daily, which improve muscle strength by increasing acetylcholine availability at neuromuscular junctions 1.
  • For patients with moderate to severe symptoms, immunosuppressive therapy is often necessary, including corticosteroids (prednisone, starting at 10-25mg daily and gradually increasing), azathioprine (2-3mg/kg/day), mycophenolate mofetil (1000mg twice daily), or cyclosporine (3-5mg/kg/day in divided doses) 1.
  • Thymectomy is recommended for patients with thymoma and for many patients under 60 with generalized myasthenia gravis, as it can reduce symptoms and medication requirements 1.
  • For myasthenic crisis, plasma exchange or intravenous immunoglobulin (IVIG at 2g/kg divided over 2-5 days) provides rapid but temporary improvement 1.
  • Patients should avoid certain medications that can worsen symptoms, including some antibiotics (fluoroquinolones, aminoglycosides), beta-blockers, and magnesium 1.
  • Regular monitoring of respiratory function is crucial, as respiratory muscles can be affected, potentially requiring ventilatory support in severe cases 1.

From the FDA Drug Label

Pyridostigmine bromide is useful in the treatment of myasthenia gravis. The treatment for myasthenia gravis is pyridostigmine (PO) 2.

  • Pyridostigmine is used to treat this condition.

From the Research

Treatment Options for Myasthenia Gravis

The treatment for myasthenia gravis (MG) can be categorized into several approaches, including:

  • Symptomatic treatment using acetylcholinesterase inhibitors, such as pyridostigmine, which is generally considered safe and effective in relieving symptoms 3
  • Immunosuppressive treatment, including corticosteroids and azathioprine, which is the mainstay of treatment for MG and can provide significant benefit in most patients 4
  • Thymectomy, which is considered in patients with thymoma or those who do not respond to immunosuppressive treatment 5

Immunotherapy and Other Treatment Approaches

Immunotherapy, including intravenous immunoglobulin and plasma exchange, can be used to treat disease exacerbations and provide fast-acting relief 5

  • Novel treatments, such as T-cell directed monoclonal antibodies and monoclonal antibodies against key B-cell molecules, are being developed and show promise in clinical trials 6
  • Other treatment approaches, including drugs that inhibit distinct elements of the complement system and cytokines, are also being explored 6

Treatment Goals and Considerations

The goal of treatment for MG is to achieve clinical remission or minimal symptoms with near-normal function and quality of life 5

  • Treatment should be tailored to the individual patient and based on their specific MG subgroup and disease severity 5
  • Active physical training should be encouraged to help manage symptoms and improve quality of life 5
  • Comorbidity is frequent, particularly in elderly patients, and should be taken into consideration when developing a treatment plan 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of myasthenia gravis: focus on pyridostigmine.

Clinical drug investigation, 2011

Research

Myasthenia gravis.

Nature reviews. Disease primers, 2019

Research

Advances and challenges in the treatment of myasthenia gravis.

Therapeutic advances in neurological disorders, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.